Impact of Bridging Response on Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma
{{output}}
Background: Bridging therapy (BT) is frequently administered during CD19 CAR T-cell manufacturing for relapsed or refractory large B-cell lymphoma (LBCL), and although disease status at infusion has been associated with outcomes,... ...
